Skip to main content
OpenTrials
Completed

NCT Number: NCT00507936

Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain

This study will compare the efficacy and the safety of ABT-894 (1mg, 2mg or 4mg capsules) administered BID to placebo in the treatment of DNP. Another treatment arm will be Duloxetine 60mg administered once daily (QD). Approximately 275 subjects will be enrolled into the study at approximately 50 sites in both the United States and Europe. The study will be divided into the following periods: Screening/Washout (21 days) followed by a Baseline Visit, an 8-week Treatment Period and a 1-week Follow-up Visit.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetic Neuralgia Diabetes Complications Diabetes Mellitus Diabetic Neuropathies Diabetic Neuropathy, Painful Diabetic Polyneuropathy Endocrine System Diseases Nervous System Diseases Neuralgia Neuralgia, Diabetic Neurologic Manifestations Neuromuscular Diseases Pain Pathological Conditions, Signs and Symptoms Peripheral Nervous System Diseases Signs and Symptoms

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Site Reference ID/Investigator# 8508, Kingston, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • If female, subject is either postmenopausal for at least two (2) years or surgically sterile or is practicing at least one (1) method of birth control.
  • If female, subject must have negative results for pregnancy tests.
  • The subject must have a diagnosis of diabetes mellitus (Type 1 or Type 2) and a diagnosis of DNP.
  • Subject's DNP must be present for a minimum of six (6) months and should have begun in the feet with relative symmetrical onset.
  • Subject has an HgbA1c <= 9. Subjects who have an HgbA1c > 9 and <= 11 may be included in the study.
  • If male, the subject is surgically sterile (vasectomy), is sexually inactive, or is using a barrier method (condom) of birth control for the duration of the study and for 7 days following the last dose of study drug.

Exclusion criteria

  • The subject has failed previous treatment with duloxetine for DNP.
  • Subject has a diagnosis of narrow-angle glaucoma.
  • Subject has a history of an allergic reaction or intolerance to duloxetine, acetaminophen, or any other NNR agonist.
  • Subject has a diagnosis of fibromyalgia that requires treatment.
  • Subject has a functioning implanted medical device (spinal cord stimulator, intrathecal pump or peripheral nerve stimulator) for the treatment of neuropathic pain.
  • Subject has a history of seizures (febrile may be ok) or major depressive episode within the past two (2) years or major psychiatric disorder including bipolar disorder, schizophrenia or borderline personality disorder.
  • Subject has a history of myocardial infarction (MI) within six (6) months of the Screening Visit.
  • Subject has unstable angina.
  • Subject has ventricular arrhythmia requiring anti-arrhythmic therapy.
  • Subject has undergone a cardiac revascularization procedure within 30 days of Screening.
  • Subject has uncontrolled hypertension (HTN) defined as a systolic blood pressure (BP) >= 160 and/or a diastolic blood pressure (BP) >= 100 at Screening and/or Baseline.
  • Subject has a clinically significant abnormal ECG at Screening
  • Subject has an active malignancy of any type or has been diagnosed with or treated for cancer within the past 5 years.
  • Subject has a positive result for drugs of abuse at Screening with the exception of a positive result for a known prescribed medication.
  • Subject's screening laboratory results show hepatitis A, B or C.
  • Subject has a known or suspected history of Human Immunodeficiency Virus (HIV).

Treatment and study plan

ABT-894

Drug

ABT-894 1 mg capsule BID throughout treatment period

Placebo

Drug

placebo capsule BID throughout the treatment period

Duloxetine

Drug

Duloxetine 60 mg QD throughout treatment period

Primary outcomes

  1. Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP

    Time frame: Change from baseline to final 24-hour average pain score

Secondary outcomes

  1. Proportions of treatment responders; subjects who complete treatment period with 30% improvement

    Time frame: From Baseline to final 24-hour average pain score

  2. Mean of 24-hour worst pain severity, average of night pain, and average of morning pain measured by the 11-point Likert scale and from subject's daily diary

    Time frame: Weekly through treatment phase

  3. Brief Pain Inventory (BPI) (short form) including Pain Severity

    Time frame: At each visit from Baseline to Week 8 visit

  4. Clinician Global Impression: Severity (CGI-S) and Patient Global Impression: Change (PGI-C)

    Time frame: At each visit from Baseline to Week 8 visit

Sponsors and collaborators

Lead sponsor

AbbVie (prior sponsor, Abbott)

Industry

Registry information

Official study title

A Global, Multicenter, Randomized, Double-Blind Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain

Important dates

Study start
2007
Primary completion
2008
Study completion
2008
First posted
Jul 27, 2007
Registry last updated
Jan 23, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.